Understanding the mechanisms that link changes in DNA methylation with histone modifications is particularly relevant in the case of tumor suppressor genes that undergo transcriptional silencing in cancer cells in association with promoter CpG island hypermethylation. In this study, we show that two histone lysine methylation marks associated with active transcription, dimethylation of H3K79 (H3K79me2) and trimethylation of H3K4 (H3K4me3), are present in all the unmethylated promoters analysed, and both of them are lost when these promoters become hypermethylated. Most importantly, pharmacological and genetic interventions that cause DNA demethylation and partial recovery of gene transcription, result in the restoration of H3K4me3, but not of H3K79me2. We also show that DOT1L, the major H3K79 histone methyltransferase, is no longer recruited to the promoters that are demethylated after 5-azadeoxycytidine treatment or genetic deletion of DNA methyltransferases. Knock-down and transfection experiments for DOT1L show that this enzyme has a direct role in maintaining the euchromatic and active status of these genes when unmethylated. These findings suggest that DNA demethylating interventions alone are not able to restore a complete euchromatic status and a full transcriptional reactivation of the epigenetically silenced tumor suppressor genes, and reinforce the necessity of targeting multiple elements of the epigenetics machinery for a successful treatment of malignancies.
Introduction
Hypermethylation of promoter CpG islands of tumor suppressor genes is one of the best-studied epigenetic alterations in cancer (Jones and Baylin, 2007; Esteller, 2008) . It results in the aberrant silencing of tumor suppressor genes and is considered to be a key mechanism by which their activity is lost in cancer (Jones and Baylin, 2007; Esteller, 2008) . In contrast to genetic mutations, which are essentially irreversible, DNA hypermethylation can be pharmacologically reversed by using small compounds (Yoo and Jones, 2006) that inhibit the activity of DNA methyltransferases (DNMTs), the enzymes that catalyse the transfer of a methyl group to the 5 0 -position of cytosines (Jones and Baylin, 2007; Esteller, 2008) . The existence of such inhibitors has stimulated intense research because of their potential use as chemotherapeutics, and several DNMT inhibitors have recently been approved for the clinical treatment of cancer (Oki et al., 2007; GarciaManero, 2008) .
In parallel with the characterization of the profile of hypermethylation in cancer cells, which has been shown to be tumor-type specific (Costello et al., 2000; Esteller et al., 2001) , during the past decade we have reached a better understanding of the mechanisms by which hypermethylation is associated with transcriptional silencing. The process has to be placed in the context of chromatin, particularly in relation to histones, the basic proteins that compose the nucleosomes around which the DNA is wrapped. Histone proteins are the target for a variety of post-translational modifications, such as acetylation, methylation, phosphorylation and ubiquitination, which constitute the second group of epigenetic modifications. Specific combinations of histone modifications are thought to form a signature that dictates specific transcriptional responses and cellular functions (Turner, 2002; Wang et al., 2008) . Although histone acetylation is generally linked to transcription, histone lysine methylation may be associated with different situations depending on the residue that is modified. Thus, di-and trimethylation of H3K4 (H3K4me2 and H3K4me3), trimethylation of H3K36 (H3K36me3) and dimethylation of H3K79 (H3K79me2) are linked with transcriptional activity, whereas di-and trimethylation occurring at H3K9, H3K27 and H4K20 is associated with gene silencing (Berger, 2007; Kouzarides, 2007) .
In recent years, compelling evidence has been found of the existence of a dynamic interplay between a particular DNA methylation status and the histone modification profile. We have learned, for instance, that at least two groups of proteins that bind methylated DNA (the methyl-CpG binding domain and Kaiso families) recruit histone modification enzymes that are able to repress transcription (Lopez-Serra and Esteller, 2008) . Further connections between DNA methylation and histone modifications are maintained by Polycomb group proteins, such as the enhancer of zeste homolog 2, which is responsible for the trimethylation of H3K27, that has also been suggested to be involved in the occurrence of DNA methylation at specific sites (Simon and Lange, 2008) .
In the context of tumor suppressor genes (TSGs), most of the current interest in the relationship between histone lysine methylation and DNA methylation has been focused on repressive marks (Fahrner et al., 2002; Nguyen et al., 2002; Ballestar et al., 2003; Kondo et al., 2003; McGarvey et al., 2006) , whereas less attention has been paid to those histone lysine methylations associated with transcriptional activity. These studies have shown that hypermethylation of CpG islands at the promoter of is additionally associated with a particular combination of chromatin modifications, such as H3K9me2/me3, trimethylation of H3K27 and the absence of the activating mark H3K4me3. These changes occur simultaneously with a decrease in the acetylation status of histones H3 and H4. The effects of DNMT inhibitors on the status of histone modifications are additional evidence of the interconnection between epigenetic modifications. Thus, the use of 5-aza-deoxycytidine (5azadC) results in the reversion of the histone acetylation status of hypermethylated genes. Inhibition of DNMTs also influences the status of histone lysine methylation (Fahrner et al., 2002; Nguyen et al., 2002; Ballestar et al., 2003; Kondo et al., 2003) . However, recent findings of McGarvey et al. suggest that hypermethylated tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state, because they maintain several repressive histone modifications marks (McGarvey et al., 2006) .
Here we have analysed the methylation status of the three lysine residues on histone H3 (K4, K36 and K79), known to be associated with active transcription, in the context of tumor suppressor genes that become hypermethylated in cancer cells. We have also analysed whether these marks are reversed after treatment with DNMTs inhibitors that result in pharmacologically induced reactivation. We have found that the active histone lysine methylation signature present at the promoter of unmethylated tumor suppressor genes, namely H3K4me3 and H3K79me2, is permanently disrupted when the gene becomes epigenetically silenced by promoter hypermethylation, because after DNA demethylation at these promoters only H3K4me3, but not H3K79me2, is re-established. To understand better the consequences of the incomplete re-establishment of the active histone lysine methylation profile at the promoter of hypermethylated tumor suppressor genes after DNA demethylation, we have tested the specific contribution of the H3K79 histone methyltransferase DOT1L Ng et al., 2002; van Leeuwen et al., 2002; Min et al., 2003) to the maintenance of the active status of promoters. Both overexpression and downregulation of DOT1L indicate that this enzyme and H3K79me2 are essential for the establishment of the correct euchromatic state and consequently for maintaining the transcriptionally active status of tumor suppressor genes. Our results provide new insights into the role of active histone lysine methylation and DNA methylation in the regulation of tumor suppressor genes (TSGs) in cancer cells and might have important implications for the development of therapeutic approaches to the complete reversal of gene silencing.
Results and Discussion
Incomplete recovery of expression levels of tumor suppressor genes in cells treated with a DNA demethylating agent In order to understand better the relationship between DNA methylation and histone lysine methylation associated with active transcription in the epigenetic disregulation of TSGs in cancer, we used two human colorectal cancer cell lines, HCT15 and HCT116, and three different TSGs of which 5 0 -CpG island DNA methylation status had been studied earlier, Ras association domain family protein 1A (RASSF1A), retinoic acid receptor B2 (RARb2) and glutathione S-transferase P1 (Jones and Baylin, 2007; Esteller, 2008) . The TSGs were chosen on the basis of the existence of a differential CpG island methylation status: the 5 0 -CpG island of RASSF1A is hypermethylated in HCT15 cells, but remains unmethylated in HCT116 cells; RARb2 CpG island is methylated in both cell lines and glutathione S-transferase P1 CpG island is unmethylated in both cell lines . We performed bisulfite genomic sequencing of multiple clones and we confirmed the reported DNA methylation patterns (Figure 1a ). The presence of 5 0 -CpG island hypermethylation was associated with the transcriptional silencing of the corresponding gene determined by quantitative reverse transcriptase (RT)-PCR ( Figure 1b) .
To characterize the dynamics of the relationship between the active histone lysine methylation and DNA methylation at the promoter of unmethylated and hypermethylated TSGs, we treated the two colorectal cancer cell lines with the DNA methyltransferase inhibitor 5 0 -aza-2 0 -deoxycytidine (5azadC) at a concentration of 1 mM for 48 h. This treatment caused significant demethylation at the promoter region of RASSF1A and RARb2 in HCT15 cells, and at RARb2 in HCT116 cells (Figure 1a ). The treatment with 5azadC resulted in restoration of the expression of these TSGs (Figure 1b) . However, when the expression levels of RASSF1A in HCT15 cells treated with 5azadC were compared with their expression levels in HCT116 cells or normal colon (n ¼ 4), in which RASSF1A is unmethylated, pharmacological demethylation was observed to cause significant but incomplete recovery of the expression levels (Figure 1b results of other studies (Cameron et al., 1999; Kondo et al., 2003) . In addition, the expression levels of the TSG RARb2, which was hypermethylated in both colorectal cancer cell lines, after pharmacological DNA demethylation did not attain the levels of RARb2 expression found in normal colon samples (n ¼ 4) (Figure 1b) . Treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid alone did not induce RASSF1A or RARb2 expression in hypermethylated cells, but together with 5azadC caused a synergistic effect, as observed earlier (Cameron et al., 1999) , although did not reach the expression levels of normal colon (Supplementary Figure 1) . In the case of RARb2, treatment with its ligand retinoic acid did not induce its expression in hypermethylated HCT116 cells, but together with 5azadC caused a synergistic effect, although it was lower than the expression levels of normal colon (Supplementary Figure 2) . We confirmed these results using an alternative model, specifically a cell line derived from HCT116 in which the two major DNMTs, DNMT1 and DNMT3b, had been genetically disrupted (HCT116 DKO) (Rhee et al., 2002) . RARb2 is unmethylated in DKO cells, although hypermethylated in its parental cell line, HCT116 ( Figure 1c ). Using this alternative model, in which the absence of DNA methylation in the context of a cancer cell line is stable, we also observed that the expression of the RARb2 gene did not attain the levels found in normal colon ( Figure 1c ).
Finally, we extended the analysis to two additional tumor suppressor genes undergoing CpG island promoter hypermethylation-associated silencing in human cancer, SFRP2 and GATA4 (Suzuki et al., 2002; Akiyama et al., 2003) . We performed bisulfite genomic sequencing of multiple clones and we observed CpG island hypermethylation for the two genes in HCT15 and HCT116 cells (Supplementary Figure 3) . The presence of 5 0 -CpG island hypermethylation was associated with the transcriptional silencing of the corresponding gene determined by quantitative RT-PCR (Supplementary Figure 3) . The treatment with 5azadC resulted in restoration of the expression of these TSGs (Supplementary Figure 3) . However, the expression levels obtained upon DNA demethylation treatment were lower in comparison with normal colon. The same incomplete recovery of the expression levels was observed in DKO cells (Supplementary Figure 3) . These findings are consistent with the results obtained above for RASSF1A and RARb2.
DNA methylation depletion at hypermethylated promoters is associated with only a partial recovery of the active histone lysine methylation signature Once the DNA methylation and transcriptional status of the above panel of TSGs had been characterized, we used chromatin immunoprecipitation (ChIP) to map the profile of histone lysine methylation for which there is a known association with an active transcriptional status, namely H3K4me3, H3K36me3 and H3K79me2 (Berger, 2007; Kouzarides, 2007) . We studied two different regions across the transcription start sites of our panel of TSGs: the first region was located in the promoter region (À0.6 to À0.3 kb) and the second one in the coding region ( þ 0.1 to þ 0.3 kb). In addition to the panel of TSGs described above, we included as a control an unmethylated gene, HOXA9, for which enrichment of H3K4me3 and H3K79me2 at its transcription start sites has already been reported Okada et al., 2005) . Our analysis showed that all unmethylated 5 0 -CpG islands of TSGs were characterized by the presence of both H3K4me3 and H3K79me2, but not of H3K36me3 ( As an unmethylated 5 0 -CpG island of a TSG is characterized by an active histone lysine methylation signature consisting of the presence of H3K4me3 and H3K79me2, we analysed whether the pharmacologically induced removal of DNA methylation would lead to the recovery of these two histone lysine methylation marks. Interestingly, we observed that treatment with 5azadC exclusively induced the re-establishment of H3K4me3 at these TSGs, whereas H3K79me2 was not recovered (Figure 2a and Supplementary Figure 3) . This was the case for RASSF1A in HCT15 cells (Figure 2a Figure 2) were also unable to recover the H3K79me2 mark. These results were confirmed using the isogenic HCT116 cells with the double defect in DNMTs. In these DKO cells, we also observed that H3K4me3, but not H3K79me2, was present surrounding the transcription start site of RARb2, SFRP2 and GATA4 (Figure 2b and Supplementary Figure 3 ). Considering all these observations DOT1L and DNA methylation FV Jacinto et al together, we can conclude that the induction of DNA hypomethylation by pharmacological inhibition or by genetic disruption of DNMTs (DNMT1 and DNMT3B) in colon cancer cells may not able to restore the euchromatic state fully, and that H3K79me2 is permanently lost.
The histone methyltransferase DOT1L is not recruited to the promoter of TSGs after DNA demethylation The K79 dimethylation at histone H3 correlating with transcriptional activation is exclusively catalysed by DOT1L Ng et al., 2002; van Leeuwen et al., 2002; Min et al., 2003) . DOT1L is an evolutionarily conserved lysine methyltransferase that catalyses the mono-, di-and trimethylation of K79 of histone H3, but unlike other lysine methyltransferases, does not contain a SET domain Ng et al., 2002; van Leeuwen et al., 2002) . Most importantly, DOT1L mistargeting has been associated with malignant transformation in human leukemia (Okada et al., 2005) . As H3K79me2 was permanently lost in the described TSGs even upon DNA demethylation events, we decided to analyse whether DOT1L was occupying the studied 5 0 -CpG islands under the range of earlier studied conditions. In parallel, we analysed the association of RNA polymerase II (RNA pol II), as a control of active transcription, and two H3K4-specific histone methyltransferases, hSET1/KMT2G and MLL1/ KMT2A . In addition, we included an antibody against WDR5, a structural component common to several H3K4 methyltransferase complexes (Wysocka et al., 2005) . ChIP experiments revealed that RNA pol II was always present at the transcription start site of unmethylated 5 0 -CpG islands of TSGs (Figure 3a) , which is indicative of active transcription. In addition, all unmethylated promoters showed the presence of WDR5 and either of the two H3K4 histone methyltransferases analysed (Figure 3a) . In most cases, MLL1 was the one present in these unmethylated promoters, although the RASSF1A promoter showed association of SET1 in HCT116 cells. Most importantly, the presence of DOT1L was shown in all the studied unmethylated 5 0 -CpG islands of TSGs (Figure 3a) .
In sharp contrast, the hypermethylated 5 0 -CpG islands of the analysed TSGs were devoid of RNA pol II and the aforementioned histone methyltransferases (SET1, MLL1 and DOT1L) (Figure 3a ), in association with the corresponding transcriptional silencing described above. The pharmacological (5azadC treatment) or genetic (DKO cells) induction of DNA hypomethylation events at the 5 0 -CpG islands of hypermethylated TSGs resulted in the recruitment of the RNA pol II and H3K4 HMTs complexes (Figures  3a and b) . Remarkably, however, the K79-specific lysine methyltransferase DOT1L was not present in these 5 0 -CpG island promoters, even when the described DNA hypomethylation events were achieved (Figures 3a  and b) . The absence of DOT1L recruitment provides an explanation for the incomplete recovery of the H3K79me2 mark in the 5 0 -CpG islands in which DNA demethylation events were observed.
Depletion of DOT1L significantly reduces the expression of unmethylated tumor suppressor genes A fundamental question that arises from our earlier observations is whether the impaired recruitment of DOT1L and subsequent absence of H3K79me2, in TSGs that are demethylated upon 5azadC treatment or in DKO cells has a direct effect on transcription. It is tempting to speculate that the partial recovery of the active histone lysine methylation signature explains the incomplete return to full transcriptionally active status once DNA demethylation is achieved. This might have profound implications for the application of therapeutic compounds that reverse DNA methylation. To address this matter, we transiently knocked down DOT1L by RNA interference in both HCT15 and HCT116 cells. Once it had been confirmed by qRT-PCR (Figure 4a ) and western blot (Figure 4b ) that the expression levels of DOT1L were significantly reduced (by around 70%), we analysed the global levels of H3K79me2 by western blot in these cells. As shown in Figure 4b , we observed a dramatic decrease in the global levels of H3K79me2, reinforcing the notion that DOT1L is the major K79 histone methyltransferase in mammalian cells.
To determine whether the absence of DOT1L and H3K79me2 was directly involved in the partial recovery of expression levels after DNA demethylation, we compared the expression levels of the aforementioned tumor suppressor gene RASSF1A in HCT15 and HCT116 cells transfected with the scramble (negative control) and DOT1L-specific small interfering RNA (siRNA) oligos (Figure 4c ). We found that DOT1L depletion reduced the expression levels of RASSF1A in HCT116 cells that are unmethylated at the RASSF1A 5 0 -CpG island (Figure 4c and Supplementary Figure 4) . No RASSF1A expression changes upon DOT1L interference were observed in the RASSF1A CpG island hypermethylated HCT15 cells (Figure 4c and Supplementary Figure 4) . We included as a control HOXA9, for which enrichment of H3K79me2 at its unmethylated 5 0 -CpG island has already been reported (Milne et al., (Figure 4c and Supplementary Figure 4) . To confirm that the expression changes were associated with a decrease in H3K79me2 levels and DOT1L recruitment in the corresponding 5 0 -CpG islands we performed ChIP assays in the DOT1L depleted cells. We found that the downregulation of DOT1L caused a significant decrease in H3K79me2 levels for RASSF1A in the unmethylated 5 0 -CpG island present in HCT116 cells (Figure 4d ) in association with a loss of DOT1L recruitment (Figure 4f ). H3K79me2 and DOT1L were absent in both scramble and DOT1L-depleted HCT15 cells that present a hypermethylated RASSF1A 5 0 -CpG island (Figures 4d and e) . DOT1L depletion also reduced the presence of the H3K79me2 mark and DOT1L recruitment in the HOXA9 5 0 -CpG island, the positive control for the described histone modification Okada et al., 2005) , in both colorectal cell lines (Figures 4d and e) . The specificity of the observed effects upon DOT1L depletion was confirmed by the absence of changes in other histone modifications, such as H3K36me3 (Supplementary Figure 4) . Most importantly, the observed diminished expression of the described genes and the loss of the H3K79me2 modification upon DOT1L depletion were not accompanied by any change in the corresponding 5 0 -CpG island DNA methylation status (Figure 4f ). These findings were extended to other tumor suppressor genes such as DKK1 and DAPK1 (unmethylated in both cell lines) that undergo CpG island promoter hypermethylation-associated silencing in human cancer (Jones and Baylin, 2007; Esteller, 2008) . DOT1L depletion reduced the expression levels of DKK1 and DAPK1 in cells that are unmethylated at their corresponding 5 0 -CpG islands (Supplementary Figure 5) . However, our data support a model in which DOT1L and H3K79me2 specifically contribute to maintain the transcriptionally active status of unmethylated tumor suppressor genes.
Overexpression of DOT1L increases the expression of unmethylated tumor suppressor genes
To analyse further, how DOT1L contributes to establish the correct euchromatic state and maintain the transcriptionally active status of unmethylated TSGs, we transfected HCT15 and HCT116 colorectal cancer cells with the pcDNA3-DOT1L expression vector. Two stable clones were obtained, both expressing high levels of DOT1L determined by qRT-PCR (Figure 5a ) and western blot (Figure 5b ). The measurement of global levels of H3K79me2 by western blot revealed that the two DOT1L-overexpressing clones had increased levels of H3K79me2 (Figure 5c ). The specificity of the approach was confirmed by the absence of changes in other histone modifications, such as H3K36me3 ( Supplementary Figure 4) . We found that DOT1L overexpression increased the expression levels of RASSF1A in HCT116 cells that are unmethylated at the RASSF1A 5 0 -CpG island (Figure 5d ). No RASSF1A expression changes upon DOT1L transfection were observed in the RASSF1A CpG island hypermethylated HCT15 cells (Figure 5d ). Most importantly, 5azadC treatment of the DOT1L-transfected HCT15 cells did not achieve further RASS-F1A reactivation than the one observed in untransfected cells upon treatment with the DNA demethylating agent (Supplementary Figure 6) . In contrast, DOT1L overexpression increased the expression levels of HOXA9 (the positive control for the H3K79me2 mark) in HCT116 and HCT15 cells (both unmethylated at the HOXA9 5 0 -CpG island) (Figure 5d ). To confirm that the increases in expression were associated with a gain in H3K79me2 levels in the corresponding 5 0 -CpG islands, we performed ChIP assays in the DOT1L transfected cells. We found that the overexpression of DOT1L caused a significant increase in H3K79me2 levels for RASSF1A in the unmethylated 5 0 -CpG island present in HCT116 cells (Figure 5e ). H3K79me2 was absent in both empty vector and DOT1L-transfected HCT15 cells that present a hypermethylated RASSF1A 5 0 -CpG island (Figure 5e ). DOT1L was not recruited to the hypermethylated RASSF1A 5 0 -CpG island in DOT1L-transfected HCT15 cells island (Supplementary Figure 6) . Most importantly, 5azadC treatment of the DOT1L-transfected cells did not achieve enrichment in H3K79me2 or DOT1L recruitment to the RASSF1A 5 0 -CpG island (Supplementary Figure 6) . DOT1L overexpression also increased the presence of the H3K79me2 mark in the HOXA9 5 0 -CpG island in both colorectal cell lines (Figure 5e ).
Overall, our data suggest that the histone methyltransferase DOT1L and the H3K79me2 histone mark Figure 3 The DOT1L is not recruited back to the transcription start site of tumor suppressor genes after pharmacologically or genetically induced DNA demethylation. (a) The recruitment of distinct lysisne histone methyltranferases to the transcription start sites of Ras association domain family protein 1A (RASSf1A), retinoic acid receptor B2 (RARb2) and glutathione S-transferase P1(GSTP1) in the two cell lines, HCT15 and HCT116, before and after a 48-h treatment with 1 mM 5-aza-deoxycytidine (5azadC) was evaluated by quantitative chromatin immunoprecipitation (qChIP). The CpG island methylation status of all genes is indicated. The HOXA9 gene was included as a positive control. qChIP experiments were performed using antibodies against RNApol II, two H3K4-specific histone methyltransferases (SET1 and MLL1), WDR5, a structural component common to several H3K4 histone methyltransferase complexes and DOT1L, the H3K79-specific histone methyltransferase. Two independent commercial antibodies against DOT1L (DOT1L 1, Novus Biologicals and DOT1L 2, from Abcam) were used. Primers amplify within 0 and À0.3 Kb relative to the transcription start site. (b) The recruitment of several lysine histone methyltransferases to the transcription start sites of RASSf1A, RARb2 and GSTP1 was also studied in DNA methyltransferases (DNMT)1/DNMT3b genetically disrupted HCT116 cells (DKO cells). As in (a), the CpG island methylation status of all genes is indicated and the HOXA9 gene was included as a positive control. Primer sequences are provided in Supplementary Table 1. DOT1L and DNA methylation FV Jacinto et al are critical for the active transcription of tumor suppressor genes with unmethylated 5 0 -CpG islands; and both are lost when these promoter regions become hypermethylated in cancer cells. Most importantly, DNA demethylation strategies are not able to reestablish the full euchromatin status, a finding that might be useful in the design of improved epigenetic treatments of cancer.
Materials and methods

Human colorectal cancer cell lines and treatments
The colon cancer cell lines HCT15, HCT116 and the double DNMT1À/À DNMT3bÀ/À (DKO) cells were cultured in Dulbecco's modified Eagle's medium with 4. 5 g/l glucose and L-glutamine supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. HCT116 and HCT15 cells were treated with the demethylating drug 5 0 -aza-2 0 -deoxycytidine (1 mM) for 72 h. HCT116 and HCT15 cells were treated with the proteasome inhibitor MG-132 (Sigma, St Louis, MO, USA) at a concentration of 10 mM for 6 h before harvesting. HCT116 and DKO cells were a generous gift from Dr Bert Vogelstein (Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, USA). The colorectal cancer cell line HCT15 was obtained from the American Type Culture Collection. Normal colon samples (n ¼ 4) from non-cancer patients were obtained from the PEBC tissue bank.
5
0 -CpG island DNA methylation analysis The DNA methylation status at the promoter region of tumor suppressor genes was established by PCR analysis of bisulfitemodified genomic DNA using sequencing of multiple clones. The bisulfite genomic sequencing primers used are shown in Supplementary Table 1 .
RNA extraction and qRT-PCR expression analysis
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. For qRT-PCR, contaminating DNA was removed using the TURBO DNA-free Kit (Ambion, Austin, TX, USA). 2 mg of RNA were reverse-transcribed using ThermoScript RT-PCR system (Invitrogen) using Oligo-dT as primer. cDNA was quantified by real-time PCR (qRT-PCR), using an ABI 7900HT sequence detection system (Applied Biosystems, Foster City, CA, USA). The PCR products were detected using the SYBR Green assay (Applied Biosystems) and relatively quantified using the standard curve method. Expression values were normalized against the expression of GAPDH, used as an endogenous control. qRT-PCR amplicons were verified by sequencing (Supplementary Figure 7) . Primers are shown in Supplementary Table 1 .
Quantitative chromatin immunoprecipitation
Chromatin immunoprecipitation assays were performed as described earlier (Ballestar et al., 2003) . Quantitative PCR analysis was performed on an ABI 7900HT sequence detection system (Applied Biosystems) with SYBR Green. Figure 7) . Primers used for quantitative chromatin immunoprecipitation assays are shown in Supplementary Table 1 .
Transient small interfering RNA transfection Cells were cultured to 40-60% confluence before washing with, and transferring to OptimMEM I medium (Invitrogen). Cells were transfected with siRNA (50 nM in final medium) using Oligofectamine (Invitrogen) according to the manufacturer's instructions. After 6 h, an equal volume of DMEM medium with 4.5 g/l glucose and L-glutamine supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin was added. Cells were harvested 24 or 48 h after transfection. DOT1L and MLL1-specific siRNA were designed and synthesized by Qiagen and a Scramble siRNA (Qiagen, Hilden, Germany) was used as a control. Two siRNA duplexes, recognizing two different sequences, were used against the DOT1L and MLL1 genes (Supplementary Table 1 ). Western blot analysis The nuclear and cytoplasmic fractions were isolated. To prepare cytoplasmic fractions, cells were scraped in 500 ml of RSB cytoplasmic lysis buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl, 3 mM MgCl 2 and protease inhibitors). After the addition of 1% NP-40, the lysate was incubated on ice for 20 min and centrifuged (2000 r.p.m., 5 min and 4 1C), and the supernatant was designated as the soluble cytoplasmic fraction. The pellet was washed once with RSB/1% NP-40 and twice with RSB before adding the NB nuclear lysis buffer (10 mM Tris-HCl pH 7.4, 400 mM NaCl, 1 mM EDTA and inhibitors), mixed thoroughly for 15 min at 41C and centrifuged (11 000 r.p.m., 5 min and 4 1C), to obtain the nuclear fraction. Nuclear proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. The primary antibodies used are described below. After secondary antibody incubations, signals were visualized by enhanced chemiluminescence.
DOT1L transfection
Colorectal cancer cell lines HCT15 and HCT116 with a plasmid containing DOT1L (pCDNA3-hDOT1L) provided by Y Zhang were transfected by electroporating 10 7 cells in 0.8 ml PBS with 40 mg of the expressing vector at 250 V and 975 mF. HCT116 and HCT15 were also transfected with a pcDNA3 empty vector and used as negative controls. After electroporation, cells were washed with PBS and seeded in fresh medium containing 20% fetal bovine serum. Transfected cells were selected in complete medium supplemented with G418 (600 mg ml À1 ). Clones expressing high levels of DOT1L protein were selected by qRT-PCR and western blotting.
Antibodies
The antibodies used in this study were anti-total histone H3 (ab1791; Abcam, Cambridge, Cambridgeshire, UK), antiH3K4me3 (ab8580; Abcam), anti-H3K36me3 (ab9050; Abcam), anti-H3K79me2_1 (ab3594; Abcam), anti-H3K79me2_2 (05-835;
